Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 13/20 | 0.50 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.50 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SNCA | P37840 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28135193 | 0.85 | DAO (0.42) | DAORIPK1CCNB2CDK1CCNB1 | |
| Triphosphate SCHEMBL28137708 | 0.82 | DAO (0.46) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL1781693 | 0.79 | RIPK1 (0.50) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL29756947 | 0.77 | DAO (0.65) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL435130 | 0.77 | DAO (0.65) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL24103159 | 0.76 | DAO (0.50) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL2595303 | 0.75 | DAO (0.53) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL575029 | 0.75 | DAO (0.53) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL30678374 | 0.75 | DAO (0.62) | DAORIPK1CCNB2CDK1CCNB1 | |
| SCHEMBL745278 | 0.75 | DAO (0.53) | DAORIPK1CCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 420 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110343104-A | A kind of synthetic method of 2- methyl -7- azaindole | 陈建江 | 2019-10-18 | — | — | CN | claimed |
| CN-102827162-A | Preparation method of 2-methyl-7-azaindole | ABA CHEMICALS SHANGHAI LTD | 2012-12-19 | — | — | CN | claimed |
| CN-122010905-A | Pyrazolyl derivatives as anticancer agents | 诺华股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-4344702-B1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2026-01-28 | — | — | EP | disclosed |
| US-20250346922-A1 | COMPOUNDS FOR IMPROVEMENT OF VIRAL PRODUCTION | TENAYA THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2025226545-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | PRETZEL THERAPEUTICS, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250243196-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION | 2025-07-31 | — | — | US | disclosed |
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | RAPPORT THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-12201617-B2 | HDAC6 inhibitors for treatment of metabolic disease and HFpEF | TENAYA THERAPEUTICS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-6312835-B1 | ALUMINUM AND BORON COMPLEXES OF 7-AZAINDOLES AND ALUMINUM COMPLEXES OF DI-2-PYRIDYLAMINES AND N-PHENYL-2-PYRIDYLAMINES | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2001-11-06 | — | — | US | disclosed |
| EP-0509974-B1 | Pyrrolo[2,3-b]pyridines having therapeutic activity and a process for the preparation thereof | ASTRA AB (SE) | 1999-01-13 | — | — | EP | disclosed |
| WO-1998036035-A1 | LUMINESCENT COMPOUNDS AND METHODS OF MAKING AND USING SAME | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1998-08-20 | — | — | WO | disclosed |
| US-5681959-A | DEPROTONATION OF A 2-AMINO-3-ALKYLPYRIDINE WITH AN ALKYLLITHIUM COMPOUND, THEN REACTION WITH AN AMIDE OR ESTER AND TREATMENT WITH A CONCENTRATED ACID FOR CYCLIZATION | MERCK, SHARP & DOHME LTD. (GB) | 1997-10-28 | — | — | US | disclosed |
| US-5439917-A | Phenyl-pyrrolo(2,3-b)pyridine antisecretory agent of gastric acid; adenosine triphosphatase enzyme inhibitor | AKTIEBOLAGET ASTRA (SE) | 1995-08-08 | — | — | US | disclosed |
| EP-0580616-A1 | NEW ACTIVE COMPOUNDS | Astra Aktiebolag (SE) | 1994-02-02 | — | — | EP | disclosed |
| CN-1067892-A | The preparation method of new pyrrolo-[2,3-b] pyridine derivate | ASTRA AB (SE) | 1993-01-13 | — | — | CN | disclosed |
| EP-0509974-A1 | Pyrrolo[2,3-b]pyridines having therapeutic activity and a process for the preparation thereof | Astra Aktiebolag (SE) | 1992-10-21 | — | — | EP | disclosed |
| WO-1992017477-A1 | NEW ACTIVE COMPOUNDS | AKTIEBOLAGET ASTRA (SE) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | DAO 1421/4885RIPK1 3954/4885CCNB2 4568/4885 |
| US-12201617-B2 | HDAC6 inhibitors for treatment of metabolic disease and HFpEF | HDAC6, HDAC1, HDAC2 | DAO 2175/4885RIPK1 3160/4885CCNB2 4711/4885 |
| US-20250243196-A1 | CITRON KINASE INHIBITORS | CHEK2, CILK1, DCK | DAO 3378/4885RIPK1 483/4885CCNB2 1118/4885 |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | ABL1, TH, CYP3A43 | DAO 213/4885RIPK1 2670/4885CCNB2 4476/4885 |
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | DAO 587/4885RIPK1 2340/4885CCNB2 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.